What is Citizens Jmp’s Forecast for NRC Q3 Earnings?

National Research Corporation (NASDAQ:NRC) – Citizens Jmp issued their Q3 2026 earnings estimates for shares of National Research in a research report issued to clients and investors on Tuesday, September 29th. Citizens Jmp analyst C. Davides forecasts that the company will post earnings per share of $0.21 for the quarter. Citizens Jmp currently has a “Market Outperform” rating and a $26.00 target price on the stock. The consensus estimate for National Research’s current full-year earnings is $0.98 per share. Citizens Jmp also issued estimates for National Research’s Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.98 EPS and FY2027 earnings at $1.05 EPS.

National Research (NASDAQ:NRC) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.15) by $0.46. National Research had a return on equity of 164.26% and a net margin of 4.18%.The firm had revenue of $35.39 million during the quarter, compared to analyst estimates of $34.90 million.

A number of other research firms have also recently weighed in on NRC. Weiss Ratings raised National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Wall Street Zen lowered shares of National Research from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

National Research Stock Performance

NASDAQ:NRC opened at $20.08 on Tuesday. The company has a debt-to-equity ratio of 13.13, a quick ratio of 0.65 and a current ratio of 0.65. The stock has a 50-day simple moving average of $20.95 and a two-hundred day simple moving average of $19.79. The firm has a market capitalization of $456.82 million, a PE ratio of 80.32 and a beta of 0.25. National Research has a 52-week low of $11.01 and a 52-week high of $23.68.

Hedge Funds Weigh In On National Research

Several institutional investors have recently bought and sold shares of NRC. Bank of New York Mellon Corp lifted its stake in National Research by 4.0% in the 1st quarter. Bank of New York Mellon Corp now owns 250,707 shares of the company’s stock worth $4,257,000 after purchasing an additional 9,730 shares in the last quarter. Heartland Advisors Inc. grew its position in shares of National Research by 374.3% during the first quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock valued at $4,027,000 after purchasing an additional 187,147 shares in the last quarter. Bank of America Corp DE grew its position in shares of National Research by 3.0% during the first quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock valued at $1,910,000 after purchasing an additional 3,323 shares in the last quarter. Fifth Third Bancorp bought a new stake in shares of National Research in the first quarter worth about $1,531,000. Finally, Quantinno Capital Management LP increased its holdings in shares of National Research by 61.3% in the first quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock worth $1,058,000 after purchasing an additional 23,682 shares during the last quarter. 47.26% of the stock is owned by hedge funds and other institutional investors.

National Research Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 9th. Investors of record on Friday, September 25th will be given a dividend of $0.16 per share. The ex-dividend date is Friday, September 25th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.2%. National Research’s dividend payout ratio is currently 256.00%.

About National Research

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC and known as NRC Health, provides market research, analytics and performance-improvement services to healthcare organizations. Its solutions are designed to help hospitals, health systems and other providers understand the experiences and expectations of patients, employees, physicians and communities.

The company’s offerings have included patient-experience measurement, employee and physician engagement surveys, reputation and brand research, community health assessments, data analytics and advisory services.